Concentration-QT modelling of the novel DHFR inhibitor P218 in healthy male volunteers.

Jӧrg Täubel Ulrike LorchGeorg FerberChristopher S SpencerAnne FreierSimon CoatesMyriam El GaaloulCristina DoniniMohamed Farouk ChughlayStephan Chalon

Published in: British journal of clinical pharmacology (2021)

Oral administration of P218 up to 1000 mg does not prolong QTcF and does not significantly change QRS or PR intervals, suggesting low risk for drug-induced proarrhythmia.

Keyphrases

drug induced
liver injury
cardiac resynchronization therapy
adverse drug
heart failure
left ventricular